I think there is the risk of a value destroying capital raise here. There is precedent with the first itrack raise at 1.40 followed up by another at 1.00. Management should put 2RT to the side for now and focus on iTrack to avoid excessive dilution at these levels. If they do a raise it seriously brings into question their ability to generate shareholder value imo.
- Forums
- ASX - By Stock
- Ann: ELX LEAD Clinical trial results
I think there is the risk of a value destroying capital raise...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
|
|||||
Last
24.0¢ |
Change
0.025(11.6%) |
Mkt cap ! $54.91M |
Open | High | Low | Value | Volume |
22.0¢ | 25.0¢ | 22.0¢ | $250.2K | 1.070M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 30000 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 3900 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 30000 | 0.240 |
1 | 20000 | 0.235 |
1 | 50000 | 0.230 |
1 | 50000 | 0.225 |
4 | 196832 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 3900 | 1 |
0.265 | 50000 | 1 |
0.270 | 130000 | 2 |
0.275 | 58000 | 2 |
0.280 | 100000 | 1 |
Last trade - 15.59pm 04/07/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |